VCYT (Veracyte) Total Current Liabilities: $56.1 Mil (As of Mar. 2026)


VCYT Veracyte Inc VCYT
75 GF Score
Price $60.38
GF Value $38.11
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Veracyte Total Current Liabilities?

Veracyte VCYT +3.24% 75 Total Current Liabilities is $56.1 Mil as of Mar. 2026. GuruFocus rates VCYT with a GF Score™ of 75/100 and a GF Value™ of $38.11 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Veracyte's total current liabilities for the quarter that ended in Mar. 2026 was $56.1


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Veracyte Total Current Liabilities Related Terms


Veracyte Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Veracyte's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veracyte Total Current Liabilities Chart

Veracyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.15 62.61 61.24 78.63 59.94

Veracyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.13 76.43 72.15 59.94 56.12
VCYT
75GF Score
Veracyte Inc VCYT
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veracyte Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Veracyte's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=25.935+4.051
+Other Current Liabilities+Current Deferred Liabilities
=28.791+1.16
=59.9

Veracyte's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=31.102+4.347
+Other Current Liabilities+Current Deferred Liabilities
=19.917+0.749
=56.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $56.1 Mil mean?
Veracyte (VCYT) has a Total Current Liabilities of $56.1 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Veracyte and its competitors.
Is Veracyte's Total Current Liabilities too high?
Veracyte's current Total Current Liabilities is $56.1 Mil. Overall, Veracyte has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's Total Current Liabilities compare to TWST and GRAL?
Veracyte's Total Current Liabilities of $56.1 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Diagnostics & Research company?
A good Total Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Veracyte and its competitors. Veracyte's current Total Current Liabilities is $56.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (VCYT) is currently considered Significantly Overvalued. The stock's GF Value™ is $38.11, compared to a current price of $60.38 — trading 58.4% above its estimated fair value. The current Total Current Liabilities is $56.1 Mil. Veracyte's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Veracyte (VCYT), the current Total Current Liabilities is $56.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Veracyte (VCYT) Overvalued in 2026?

Based on GuruFocus' analysis, Veracyte stock appears to be overvalued. The current stock price of $60.38 is trading 58.4% above its estimated GF Value™ of $38.11. GuruFocus considers Veracyte to be Significantly Overvalued.

Key valuation signals for VCYT:

  • Total Current Liabilities: $56.1 Mil
  • GF Value™: $38.11 vs. price of $60.38 (58.4% above fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Veracyte Business Description

Other Exchanges 12V:Germany
Address 6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
75GF Score

Get the complete analysis for VCYT

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$60.38
Price
$38.11
GF Value